The Role of the PMCPA in Advertising Compliance
Introduction to Pharmaceutical Promotion Rules
Pharmaceutical promotion in the UK is governed by a dual system: statutory regulation through the MHRA and self-regulation through the Prescription Medicines Code of Practice Authority (PMCPA). The PMCPA administers the ABPI Code of Practice, which sets standards for advertising, promotional material, and interactions with healthcare professionals.

This article explains how the PMCPA works alongside the MHRA to police pharmaceutical promotion, ensuring that marketing claims are accurate, balanced, and compliant with legal requirements.
How the PMCPA Operates as a Self-Regulatory Body
The PMCPA is independent of the ABPI but funded by it. It handles complaints about promotional materials, company behaviour, and breaches of the ABPI Code. Its rulings are published and can lead to sanctions such as audits, corrective statements, or suspension from ABPI membership.
The MHRA, by contrast, enforces the Human Medicines Regulations 2012. It can prosecute companies for illegal advertising, issue recalls, or require pre-vetting of materials. The two bodies share information but have distinct roles: the PMCPA focuses on ethical standards, while the MHRA enforces the law.
Key Mechanisms of Collaboration
The PMCPA and MHRA coordinate through regular meetings and a memorandum of understanding. When the PMCPA identifies a potential legal breach, it refers the case to the MHRA. Conversely, the MHRA may pass ethical concerns to the PMCPA.
"Self-regulation is not a substitute for statutory enforcement, but it provides a faster, industry-led route to compliance."
The PMCPA also runs a pre-vetting service for certain materials, which helps companies avoid legal pitfalls before publication. The MHRA can then focus on serious or repeat offenders.
Complaint Handling and Sanctions
Complaints to the PMCPA can come from competitors, health professionals, or the public. The process involves a case preparation, a panel hearing, and an appeal route. Sanctions include:
- Requiring the company to withdraw or amend the material.
- Publishing the case in the PMCPA's quarterly review.
- Recommending an audit of the company's procedures.
The MHRA can impose fines, imprisonment, or prohibit a company from advertising for up to two years. The table below compares the two bodies.
| Feature | PMCPA | MHRA |
|---|---|---|
| Legal basis | ABPI Code (voluntary) | Human Medicines Regulations 2012 |
| Sanctions | Audit, corrective statement, suspension | Fine, prosecution, prohibition |
| Speed | Weeks to months | Months to years |
Challenges and Future Directions
One challenge is ensuring consistent interpretation across digital and social media promotion. The PMCPA has issued guidance on influencer marketing and online content, while the MHRA has updated its own guidance on electronic advertising.
- Both bodies now emphasise transparency in payments to healthcare professionals.
- Joint training sessions help industry understand overlapping requirements.
- Brexit has not changed the core framework, but UK-specific guidance is evolving.
Ultimately, the PMCPA and MHRA form a complementary system. Self-regulation catches most issues quickly, while statutory enforcement handles serious or persistent non-compliance. Companies that ignore both risk reputational damage and legal penalties.
